Wikipedia:Version 1.0 Editorial Team/Pharmacology articles by quality log
This is a log of operations by a bot. The contents of this page are unlikely to need human editing. In particular, links should not be disambiguated as this is a historical record. |
May 28, 2024[edit]
Reassessed[edit]
- 2-MDP (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Benzoctamine (talk) reassessed. Quality rating changed from Start-Class to C-Class. (rev · t)
Removed[edit]
- Draft:Rafeeq Habeeb Ph.D (talk) removed.
May 27, 2024[edit]
Assessed[edit]
- Draft:Ning Zheng (talk) assessed. Importance assessed as NA-Class. (rev · t)
May 26, 2024[edit]
Reassessed[edit]
- American Pharmacists Association (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Piperacillin (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t)
Assessed[edit]
- CDD-2807 (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
May 25, 2024[edit]
Reassessed[edit]
- Amrinone (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- BAY 73-6691 (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Carteolol (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Daprodustat (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Etrasimod (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Fezolinetant (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Nirogacestat (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Orteronel (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Perfluorohexyloctane (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Pirtobrutinib (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Repotrectinib (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Rezafungin (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Ritlecitinib (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Sotagliflozin (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Sparsentan (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Tiratricol (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Zilucoplan (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Β-Methylphenethylamine (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
May 24, 2024[edit]
Reassessed[edit]
Removed[edit]
- Draft:Mayur Shetty (talk) removed.
May 23, 2024[edit]
Reassessed[edit]
- Pharmaceutical industry in China (talk) reassessed. Quality rating changed from Start-Class to B-Class. (rev · t) Importance rating changed from Mid-Class to High-Class. (rev · t)
- Pharmaceutical industry in the United Kingdom (talk) reassessed. Quality rating changed from Start-Class to C-Class. (rev · t) Importance rating changed from Unknown-Class to High-Class. (rev · t)
Assessed[edit]
- Depyrogenation (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
May 22, 2024[edit]
Reassessed[edit]
- Etodesnitazene (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Tomáš Cihlář (talk) reassessed. Quality rating changed from B-Class to C-Class. (rev · t)